HI
ITCI

Handelsinvest Investeringsforvaltning’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Handelsinvest Investeringsforvaltning’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$223K Sell
3,217
-1,670
-34% -$115K 0.11% 244
2023
Q4 		$350K Buy
+4,887
New +$281K 0.14% 225

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Handelsinvest Investeringsforvaltning's ITCI Position: Q1 2024 in Review

Handelsinvest Investeringsforvaltning reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 34% in Q1 2024, selling an estimated $115K and leaving 3,217 shares worth $223K. The position accounts for 0.11% of the portfolio, ranked #244.

Handelsinvest Investeringsforvaltning first reported a position in ITCI in Q4 2023 and has held it in 2 quarters since. The position peaked at $350K in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Handelsinvest Investeringsforvaltning held 3,217 shares of Intra-Cellular Therapies Inc. worth $223K as of Q1 2024.
  • Handelsinvest Investeringsforvaltning sold 1,670 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $115K.
  • Intra-Cellular Therapies Inc. made up 0.11% of Handelsinvest Investeringsforvaltning's portfolio in Q1 2024, its #244 holding.
  • Handelsinvest Investeringsforvaltning first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and has held it in 2 quarters since.
  • Handelsinvest Investeringsforvaltning's Intra-Cellular Therapies Inc. position peaked at $350K in Q4 2023.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Handelsinvest Investeringsforvaltning's 13F filing for Q1 2024, filed 19 Apr 2024.